Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
AY Lin
Observed names:
A.Y. Lin,
Aaron Lin,
Aaron Y. Lin
Institution:
The Netherlands Cancer Institute
Observed institutions:
Merck KGaA, Darmstadt (Germany),
The Netherlands Cancer Institute,
University of Pittsburgh Medical Center,
Gilead Sciences (United States)
ORCID:
0009-0008-7519-0853
Observed ORCID:
0009-0008-7519-0853
OpenAlex ID:
A5108805147
EE456 Cost-Effectiveness of Tenofovir Alafenamide (TAF) for Treatment of Chronic Hepatitis B in Taiwan
2022
·
ECH Tan
, A Yehoshua
, et al.
·
Value in Health
·
2
POSA128 Cost-Effectiveness Analysis of Avelumab Plus Best Supportive Care (BSC) vs BSC Alone as a First-Line (1L) Maintenance Treatment for Patients With Locally Advanced or Metastatic Urothelial Carcinoma in Taiwan
2022
·
WC Chang
, Y Xiao
, et al.
·
Value in Health
·
2
PDF
CfDNA-based copy-number dynamics during anti-PD1 treatment in metastatic triple negative breast cancer
2025
·
Aaron Y. Lin
, Olga I. Isaeva
, et al.
·
Cell Reports Medicine
·
1
474P ctDNA-based copy number dynamics during anti-PD1 treatment in patients with metastatic triple-negative breast cancer
2023
·
A.Y. Lin
, O.I. Isaeva
, et al.
·
Annals of Oncology
PDF
POSA70 Budget Impact Analysis of Avelumab Plus Best Supportive Care (BSC) vs BSC Alone as First-Line (1L) Maintenance Treatment in Patients With Locally Advanced (LA) or Metastatic Urothelial Carcinoma (mUC) in Taiwan
2022
·
YC Tsai
, AY Lin
, et al.
·
Value in Health
203a: Bmp-2-mediated Regeneration of Large Scale Cranial Defects in the Canine: an Examination of Different Carriers
2010
·
CR Kinsella
, MB Bykowski
, et al.
·
Plastic & Reconstructive Surgery
Show more works
View as search
Works count:
7
Citation count:
5
H-index:
2
I10-index:
Year
Topic
Type